Skip to content
Subscribe

Feds Give Research on Medical Marijuana and PTSD Green Light

Feds Give Research on Medical Marijuana and PTSD Green Light
Published:

A study that would explore the possible benefits of marijuana for those who suffer post-traumatic stress disorder got a huge green light from the federal government.The research project, headed by Dr. Suzanne Sisley of the University of Arizona, already had approval from the U.S. Food and Drug Administration (FDA).

But, like a lot of studies involving pot, it hit a bottleneck in trying to obtain cannabis from the only legitimate place it could — the National Institute on Drug Abuse’s (NIDA) sole marijuana farm in Mississippi.

Critics say NIDA has long been wary of attempts to prove that marijuana has medicinal benefits. But, in a move hailed as tacit approval for the study by the Obama administration itself, the PTSD research received approval to receive federal weed.

According to a statement from the Multidisciplinary Association for Psychedelic Studies (MAPS):

On March 14, 2014, in an historic shift in federal policy, the U.S. Department of Health and Human Services granted permission for MAPS to purchase research-grade marijuana from the National Institute on Drug Abuse (NIDA) for our planned study of marijuana for symptoms of PTSD in U.S. veterans.

The group says this is the first time in 22 years of trying that feds have granted access to this sole source of legit, United States-produced cannabis.

However, MAPS says the study still requires approval from the DEA. The research will also need cash from supporters, the group says. The organization previously described the research as a:

...placebo-controlled, triple-blind, randomized crossover pilot study is the first of its kind, and will investigate the safety and efficacy of marijuana for PTSD in veterans using four marijuana strains each with a different level of D9-tetrahydrocannabinol (THC) along with a fifth strain containing equal amounts of THC (6%) and cannabidiol (CBD) (6%). PTSD symptoms will be compared across conditions during four weeks of self-administration to determine if strain potency or drug delivery method affects PTSD severity.

Good luck.

Editor's note: This article originally published on the 420 Times on March 18, 2014.

Photo Credit: Kenny Holston /Flickr

Adhere to the IVN etiquette

By posting a comment, you agree to adhere to our etiquette rules: No partisan attacks, no personal attacks, substantiate your sources, no self-promotion.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Republish this article

Republishing guidelines

Republish IVN articles for free. Independent Voter News articles may be republished online or in print under a Creative Commons BY-NC-ND 4.0 license, on these terms:

  1. Credit the author and IVN. Keep the byline ("By Author Name, Independent Voter News") and the attribution note at the end, which links to the original.
  2. Keep the meaning. You may update time and place references and apply your house style. You may trim for length, as long as the cuts don't change the meaning or misrepresent the author. Keep the headline. Mark any additions as your own (for example "Additional reporting by ...").
  3. Translations are welcome. Translate faithfully, add "Translated from English by [your outlet]", and tell us at editor@ivn.us.
  4. Keep the links, including the link to the original article.
  5. Keep the tracking image. The HTML includes a 1-pixel image that counts readers on your page. It collects no personal information.
  6. Photos and illustrations. Images credited to IVN may be used with this article only. Images credited to others (AP, Getty, Unsplash, Wikimedia and so on) stay under their owners' terms. Secure the rights or switch "Include images" off.
  7. Don't sell it. You can't sell our articles or sell ads specifically against them. Your normal site advertising is fine.
  8. No implied endorsement. Don't suggest that IVN or the author endorses you, your candidates or your causes, or that donations to you support IVN.
  9. Keep labels. Opinion or analysis pieces keep that label.
  10. Point search engines to the original. Where your CMS allows, set the canonical URL to the original IVN article.
  11. No bulk or automated republishing, and don't submit our articles to aggregators (Apple News, Google News, MSN) as your own.
  12. Corrections and removals. Update your copy when we correct it, and remove it promptly if we ask. We'll contact you at the email you give us.
  13. Questions or print republication: editor@ivn.us.

IVN staff: fill in who you're inviting above, then create the invite.

Preparing the article

Feds Give Research on Medical Marijuana and PTSD Green Light

Choose a format
  • HTML
  • Email HTML
  • Markdown
  • Formatted (.docx)
  • Plain text
  • WordPress blocks
  • PDF
Choose a platform

Photos credited to others need their owners' permission.

To for

Republishing somewhere else? Questions? editor@ivn.us